Profusa Signs Binding Option to Acquire G3 Vision Labs, Potential Change of Control
PFSA is trading near its 52-week low of $0.861 (0.1% below the low) on elevated volume (3.7× avg).
Summary
Profusa signed a binding option agreement to acquire G3 Vision Labs, a commercial-stage diagnostics company. The deal involves immediate equity consideration that could result in a change of control. This follows a non-binding term sheet announced on July 27, and the binding nature and control implications represent a material escalation. The acquisition brings ~$111M in estimated 2025 revenue, a transformative scale for a company with a market cap near $560K. The reverse split on July 7 adjusted the share structure, but the equity issuance here could still be highly dilutive. Watch for the definitive agreement and shareholder vote, as the change-of-control provision may trigger further regulatory or exchange review.
At the time of this announcement, PFSA was trading at $0.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $561.8K. The 52-week trading range was $0.86 to $1,425.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.